12.02
-0.14 (-1.11%)
| Penutupan Terdahulu | 12.15 |
| Buka | 12.16 |
| Jumlah Dagangan | 1,890,462 |
| Purata Dagangan (3B) | 5,731,088 |
| Modal Pasaran | 8,746,319,872 |
| Harga / Pendapatan (P/E TTM) | 2.17 |
| Harga / Jualan (P/S) | 73.16 |
| Harga / Buku (P/B) | 1.63 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Feb 2025 - 17 Feb 2025 |
| Margin Keuntungan | 3,725.10% |
| Margin Operasi (TTM) | -7,446.10% |
| EPS Cair (TTM) | 5.54 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 22.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.94% |
| Nisbah Semasa (MRQ) | 10.43 |
| Aliran Tunai Operasi (OCF TTM) | -778.54 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -472.58 M |
| Pulangan Atas Aset (ROA TTM) | -18.44% |
| Pulangan Atas Ekuiti (ROE TTM) | 128.96% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Roivant Sciences Ltd. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.50 |
|
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 28.92% |
| % Dimiliki oleh Institusi | 79.48% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Sb Investment Advisers (Uk) Ltd | 30 Sep 2024 | 65,934,074 |
| Qvt Financial Lp | 30 Sep 2024 | 65,793,779 |
| Patient Square Capital Lp | 30 Sep 2024 | 12,228,465 |
| Julat 52 Minggu | ||
| Median | 18.00 (49.81%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 13 Nov 2024 | 18.00 (49.81%) | Beli | 11.95 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |